Michael Douvas is an Oncology physician affiliated with University of Virginia. OpenAlex indexes 36 publications with 1,115 citations (h-index 8); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1240 Lee St
Charlottesville, VA 229080817
Telephone
434-924-9333Provider last certified this registry record 30 Jul 2021.
Clinical trials
- Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL
Sponsor: University of Virginia
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SOBI, INCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
61.6%Kinase inhibitor43.3%Sprycel31%Imatinib Mesylate26%Sorafenib15%Sunitinib Malate15%Calquence14%Part D<11 patientsThalidomide Analog11.3%Revlimid52%Pomalyst48%Part D<11 patients+ 1 more class in this area
Cardiovascular
10.8%Calcium channel blocker5.4%Amlodipine Besylate100%Part D<11 patientsLoop diuretic5.4%Furosemide100%Part D<11 patientsBlood & clotting
7.4%Factor Xa inhibitor7.4%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Charles Landen, MD
University of Virginia
Stephen Caldwell
University of Virginia
James Platts-Mills, MD
University of Virginia
Eric Houpt
University of Virginia
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”